AUSTIN, Texas, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions for diseases with unmet medical need, today reported financial results for the third quarter ended September 30, 2019 and corporate highlights.
“We are excited about our pivotal Phase 3 PEACE trial in Arginase 1 Deficiency (ARG1-D), given the positive 20-dose data from our completed Phase 1/2 trial and ongoing Phase 2 open-label extension trial for pegzilarginase in patients with ARG1-D,” said Anthony G. Quinn, M.B Ch.B, Ph.D., president and chief executive officer of Aeglea. “Additionally, we are delighted to welcome Dr. Ravi Rao as chief medical officer and Mike Hanley as chief commercial officer, key executive leadership team additions who will help shape our future and continue the momentum of our ARG1-D, homocystinuria and cystinuria programs.”
- Aeglea presented positive 20-dose data on 14 patients from the Company’s completed Phase 1/2 trial and ongoing Phase 2 open-label extension (OLE) trial for pegzilarginase in patients with ARG1-D at the 2019 Symposium of the Society for the Study of Inborn Errors of Metabolism (SSIEM). All patients achieved a substantial reduction in plasma arginine with the median reduction of 274 µm from baseline to 20 doses. Aeglea reported 79% (11 of 14) of patients were clinical responders, using mobility assessment components that correspond with the PEACE trial’s secondary endpoint. Pegzilarginase was well tolerated and the rates of treatment-related adverse events decreased over time.
- Data from 10 patients dosed subcutaneously (sc) with pegzilarginase in the ongoing OLE trial for ARG1-D demonstrated that sc administration of pegzilarginase controls plasma arginine levels. All 10 patients remain on pegzilarginase sc with no patient discontinuations.
- Mike Hanley joined Aeglea as Chief Commercial Officer in October 2019. Mr. Hanley was previously Vice President and U.S. Chief Commercial Officer for Esteve Pharmaceuticals. He also served as Group Vice President and General Manager, Orphan Business Unit for Horizon Therapeutics. Mr. Hanley has 20 years of commercial leadership experience in the life sciences industry.
- Dr. Ravi Rao joined the Company as Chief Medical Officer in November 2019. Dr. Rao comes to Aeglea from GlaxoSmithKline, where he served as Vice President, Global Medical Affairs Head, Immunology and Specialty Franchise, leading programs across a number of emerging disease areas. Dr. Rao completed his residency training in London and is a Member of the Royal College of Physicians, London. He received his MB. BChir from Cambridge University and his Ph.D. in vascular biology from Imperial College, London in the United Kingdom and completed a postdoctoral fellowship at Harvard Medical School.
Aeglea will be attending the following investor conferences, with details regarding the date and time of the presentations and webcasts to be announced prior to the events.
- Jefferies 2019 London Healthcare Conference, November 20-21, London, UK
- Evercore ISI HealthCONx, December 3, Boston, MA
- Piper Jaffray Healthcare Conference, December 4-5, New York, NY
Aeglea will present a poster presentation titled “Impact of Enzymatic Degradation of Plasma Cystine in a Mouse Model of Cystinuria Under Dehydration Challenge” on Thursday, November 7th from 10:00 a.m. - 12:00 p.m. ET at the American Society of Nephrology Kidney Week annual meeting being held November 5 – 10 at the Walter E. Washington Convention Center in Washington, DC.
The Company expects to discuss the trial design for the AEB4104 program for homocystinuria during the investor conferences in the fourth quarter of 2019, prior to its filing of an IND or CTA in the first quarter of 2020.
Third Quarter 2019 Financial Results
As of September 30, 2019, Aeglea had available cash, cash equivalents, marketable securities and restricted cash of $90.2 million. Based on Aeglea’s current operating plan, management believes it has sufficient capital resources to fund anticipated operations through the first quarter of 2021.
Research and development expenses totaled $17.8 million for the third quarter of 2019, compared with $8.9 million for the third quarter of 2018. The increase was primarily due to investing in manufacturing and pre-commercial activities for Aeglea’s lead product candidate, pegzilarginase, a ramp-up in toxicology, IND-enabling studies, and manufacturing activities for the Company’s AEB4104 program for homocystinuria, and expanded clinical development activity and personnel-related expenses.
General and administrative expenses totaled $4.3 million for the third quarter of 2019, compared with $3.3 million for the third quarter of 2018. This increase was primarily due to additional employee headcount, compensation, and facilities to support company growth.
Net loss totaled $21.6 million and $11.9 million for the third quarter of 2019 and 2018, respectively, with non-cash stock compensation expense of $1.4 million and $1.1 million for the third quarter of 2019 and 2018, respectively.
About Pegzilarginase in Arginase 1 Deficiency
Pegzilarginase is an enhanced human arginase that enzymatically depletes the amino acid arginine. Aeglea is developing pegzilarginase for the treatment of patients with Arginase 1 Deficiency, a rare debilitating disease presenting in childhood with persistent hyperargininemia, severe progressive neurological abnormalities and early mortality. Pegzilarginase is intended for use as an enzyme replacement therapy in patients to reduce elevated blood arginine levels. Aeglea’s Phase 1/2 and Phase 2 OLE data for pegzilarginase in patients with Arginase 1 Deficiency demonstrated clinical improvements and sustained lowering of plasma arginine. The Company’s single, global pivotal Phase 3 PEACE trial is designed to assess the effects of treatment with pegzilarginase versus placebo over 24 weeks with a primary endpoint of plasma arginine reduction.
About Aeglea BioTherapeutics
Aeglea is a clinical-stage biotechnology company that engineers next-generation human enzymes with enhanced properties and novel activity to provide solutions for diseases with unmet medical need. Aeglea is developing pegzilarginase, its lead product candidate, for the treatment of Arginase 1 Deficiency which has received both Rare Pediatric Disease and Breakthrough Therapy Designation. Aeglea has two programs in IND-enabling studies for Homocystinuria and Cystinuria and an active discovery pipeline. For more information, please visit http://aegleabio.com.
Safe Harbor / Forward-Looking Statements
This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, statements we make regarding our cash forecasts, the timing and success of our clinical trials and related data, the timing and expectations for regulatory submissions and approvals, timing and results of meetings with regulators, the potential for expeditated development and review of pegzilarginase as of a result of the Breakthrough Therapy designation, the timing of announcements and updates relating to our clinical trials and related data, our ability to enroll patients into our clinical trials, success in our collaborations and the potential therapeutic benefits and economic value of our lead product candidate or other product candidates. Further information on potential risk factors that could affect our business and its financial results are detailed in our most recent Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 filed with the Securities and Exchange Commission (SEC), and other reports as filed with the SEC. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Sharon Merrill Associates
Director, Finance & Investor Relations
Aeglea BioTherapeutics, Inc.
Condensed Consolidated Balance Sheets
(In thousands, except share and per share amounts)
|September 30,||December 31,|
|Cash and cash equivalents||$||24,545||$||22,461|
|Prepaid expenses and other current assets||3,930||2,158|
|Total current assets||92,630||76,671|
|Property and equipment, net||980||1,018|
|Operating lease right-of-use assets||4,872||—|
|Other non-current assets||114||50|
|LIABILITIES AND STOCKHOLDERS’ EQUITY|
|Operating lease liabilities||289||—|
|Accrued and other current liabilities||12,676||9,576|
|Total current liabilities||15,396||10,239|
|Non-current operating lease liabilities||4,867||—|
|Other non-current liabilities||38||72|
|Preferred stock, $0.0001 par value; 10,000,000 shares authorized |
as of September 30, 2019 and December 31, 2018; no shares issued
and outstanding as of September 30, 2019 and December 31, 2018
|Common stock, $0.0001 par value; 500,000,000 shares authorized |
as of September 30, 2019 and December 31, 2018; 28,923,241 shares
and 24,140,097 shares issued and outstanding as of September 30, 2019
and December 31, 2018, respectively
|Additional paid-in capital||253,334||184,314|
|Accumulated other comprehensive income (loss)||78||(27||)|
|TOTAL STOCKHOLDERS’ EQUITY||79,795||67,428|
|TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY||$||100,096||$||77,739|
Aeglea BioTherapeutics, Inc.
Condensed Consolidated Statements of Operations
(In thousands, except share and per share amounts)
|Three Months Ended |
|Nine Months Ended |
|Research and development||17,839||8,929||47,034||24,921|
|General and administrative||4,307||3,314||11,391||9,125|
|Total operating expenses||22,146||12,243||58,425||34,046|
|Loss from operations||(22,146||)||(12,243||)||(58,425||)||(30,158||)|
|Other income (expense):|
|Other expense, net||(12||)||(13||)||(45||)||(37||)|
|Total other income||573||326||1,666||708|
|Net loss per share, basic and diluted||$||(0.66||)||$||(0.54||)||$||(1.80||)||$||(1.49||)|
|Weighted-average common shares outstanding, basic and |